ATXI OTC
Avenue Therapeutics, Inc.
1W: -18.5%
1M: -28.5%
3M: +23.5%
YTD: -40.6%
1Y: -43.4%
3Y: -99.2%
5Y: -100.0%
$0.41
+0.05 (+13.22%)
Weekly Expected Move ±37.9%
$0
$0
$0
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.3M
52W Range0.15-0.9699
Volume1,082
Avg Volume5,275
Beta-0.17
Dividend—
Analyst Ratings
Company Info
CEOAlexandra MacLean
Employees1
SectorHealthcare
IndustryBiotechnology
IPO Date2017-06-27
Websiteavenuetx.com
1111 Kane Concourse
Bay Harbor Islands, FL 33154
US
Bay Harbor Islands, FL 33154
US
781 652 4500
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fortress Biotech, In | A-Award | 111,209 | — | 2026-01-02 |
| Fortress Biotech, In | A-Award | 33,724 | — | 2025-03-31 |
| Fortress Biotech, In | 0 | — | 2024-12-31 | |
| Herskowitz Neil | S-Sale | 23 | $2.00 | 2024-12-02 |
| KRANZLER JAY D | S-Sale | 61 | $2.24 | 2024-11-05 |